Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
11.91
Oct 23 • 3:59 PM ET Dollar change-0.41 Percentage change(-3.37%)
Aftermarket Close
11.91
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
926.27M
Enterprise Value
2.44B
Income
13.01M
Sales
1.66B
Book/sh
13.41
Cash/sh
4.01
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
4427
IPO
Aug 16, 1995
P/E
72.40
Forward P/E
4.99
PEG
1.46
P/S
0.56
P/B
0.89
P/C
2.97
P/FCF
35.90
EV/EBITDA
7.07
EV/Sales
1.47
Quick Ratio
2.11
Current Ratio
3.60
Debt/Eq
1.71
LT Debt/Eq
1.71
Option/Short
Yes / Yes
EPS (ttm)
0.16
EPS next Y
2.39
EPS next Q
0.64
EPS this Y
5.02%
EPS next Y
1.86%
EPS next 5Y
3.41%
EPS past 3/5Y
- -
Sales past 3/5Y
1.63% 3.57%
EPS Y/Y TTM
98.56%
Sales Y/Y TTM
0.84%
EPS Q/Q
368.47%
Sales Q/Q
2.27%
Insider Own
14.48%
Insider Trans
0.00%
Inst Own
94.69%
Inst Trans
-1.64%
ROA
-0.20%
ROE
1.24%
ROIC
0.45%
Gross Margin
54.84%
Oper. Margin
11.67%
Profit Margin
0.79%
SMA20
-13.39%
SMA50
-22.38%
SMA200
-15.43%
Trades
Shs Outstand
77.77M
Shs Float
66.51M
52W High
20.49 -41.87%
52W Low
8.70 36.90%
Volatility
7.26% 5.57%
ATR (14)
0.80
RSI (14)
33.12
Beta
1.27
Rel Volume
1.27
Avg Volume
955.79K
Volume
1,212,712
Perf Week
-9.84%
Perf Month
-25.00%
Perf Quarter
-39.02%
Perf Half Y
12.68%
Perf YTD
-4.11%
Perf Year
-25.00%
Perf 3Y
-67.96%
Perf 5Y
-83.18%
Perf 10Y
-70.76%
Prev Close
12.32
Price
11.91
Change %
-3.37%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 11 '26Option Exercise0.0018,922040,612Mar 12 06:10 PM
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 10 '26Option Exercise0.001,216023,152Mar 12 06:10 PM
Poul MojdehPresident & CEOJan 06 '26Option Exercise0.001,39001,390Jan 07 04:10 PM
GRAVES JEFFREY ADirectorNov 05 '25Buy11.359,000102,15041,086Nov 06 04:05 PM
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
CEODr. Stuart M. Essig Ph.D.
Executive VP & CFOMs. Lea Daniels Knight
Executive Vice President of Tissue Reconstruction and Distributed TechnologiesMr. Robert T. Davis Jr.
Executive VP & Chief Commercial OfficerMr. Michael J. McBreen
Executive VP & President of International BusinessMr. Harvinder Pal Singh